• Home
• News Archive
• 21st June iBET/ITQB Seminar: An individualized system medicine platform to guide treatment decisions for therapy-resistant Acute Myeloid Leukemia

The Institute for Molecular Medicine Finland FIMM is an international, multi-disciplinary research institute focusing on building a bridge from discovery to medical applications. Research at FIMM involves the combination of high-quality science with unique patient materials and state-of-the-art technologies that range from high throughput screening, next generation sequencing, proteomics, metabolomics, imaging to bioinformatics. One of the major focuses at the institute is individualized system medicine (ISM) to treat acute myeloid leukemia (AML). The aim is to utilize cutting-edge technologies for AML patient sample analyses including next-gen genomic and transcriptomic sequencing, proteomics and high-throughput drug screening. Integrative processing of datasets generated from these analyses is used to identify patient specific biomarkers and to determine novel therapeutic options.